There have been reports of noninfectious pneumonitis (including some with pulmonary hypertension as a secondary event), infections, and renal failure (including acute renal failure) in patients...
Advanced HR+, HER2-Negative Breast Cancer
AFINITOR provides once-daily dosing
The recommended starting dose of AFINITOR® (everolimus) Tablets in advanced HR+, HER2-negative breast cancer is 10 mg once daily, regardless of age, gender, or renal function.1
AFINITOR should be1:
AFINITOR tablets should not be crushed or broken. Patients should not take tablets that are crushed or broken.
No office visits required for administration.
Storage and handling1
Avoid the use of strong CYP3A4/PgP inhibitors1
Use caution when coadministering with moderate CYP3A4/PgP inhibitors1
Avoid the use of strong CYP3A4/PgP inducers1
AFINITOR offers the flexibility of 4 dosing strengths:
10-mg, 7.5-mg, 5-mg, and 2.5-mg tablets
HER2, human epidermal growth factor receptor 2; HR+, hormone receptor-positive; PgP, P-glycoprotein.
Reference: 1. Afinitor [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; 2016.
AFINITOR is indicated for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer (advanced HR+ BC) in combination with exemestane after failure of treatment with letrozole or anastrozole.
Important Safety Information
AFINITOR is contraindicated in patients with hypersensitivity to everolimus, to other rapamycin derivatives, or to any of the excipients.
Angioedema With Concomitant Use of Angiotensin-Converting Enzyme (ACE) Inhibitors
Impaired Wound Healing
Laboratory Tests and Monitoring
Please see full Prescribing Information.